Efficacy and tolerance of a 6-month treatment course of daily interferon-α2a for chronic hepatitis C with cirrhosis

Journal of Viral Hepatitis

Volumn 4, Issue 5, 1997, Pages 317-323

  Farrell, G ^a   Cooksley, W G E ^b,j   Dudley, F J ^j   Watson, K ^c,j   McIvor, C ^b   Smith, B ^c   Jackson, P ^c   Brotodihardjo, A ^d   Farrell, G C ^d   Jones, D B ^e   Ngu, M ^e   McCaughan, G W ^f   O'Brien, E ^f   Kavanagh, J ^f   Morrow, A W ^f   Dudley, F ^g   Cromie, S ^g   Jenkins, P ^g   Harley, H ^h   Shaw, D ^h   Batey, R G ⁱ   more..

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Department of Geriatric Medicine   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g ALFRED HOSPITAL   (Australia)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

ⁱ JOHN HUNTER HOSPITAL   (Australia)

^j NONE

more..

Author keywords

Adverse effects; Chronic hepatitis C; Cirrhosis; Daily therapy; Genotypes 2 and 3; Interferon 2a

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ANTIVIRUS AGENT; INTERFERON-ALPHA 2; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD; CLASSIFICATION; CLINICAL TRIAL; DRUG TOLERANCE; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031225403     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00062.x     Document Type: Article

References (36)

1. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
2. Mattsson L, Sönnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993; 13: 274-278.
3. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993; 119: 110-115.
4. Strasser SI, Watson KJR, Lee CS, Coghlan PJ, Desmond PV. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection. Med J Aust 1995; 162: 355-358.
5. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
6. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340.
7. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
8. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
9. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
10. Lin R, Schoeman MN, Craig PI et al. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust NZ J Med 1991; 21: 387-392.
11. Marcellin P, Boyer N, Giostra E et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
12. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
13. Sáez-Royuela F, Porres JC, Moreno A et al. High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 13: 327-331.
14. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon α-2b. A multicenter study. Dig Dis Sci 1993; 38: 612-618.
15. Benelux multicentre trial study group. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard vs high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993; 34 (suppl.): S119-S120.
16. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.
17. 2b for 60 weeks. Hepatology 1994; 19: 280-285.
18. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
19. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
20. Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau J-M, le Groupe Français pour l'Étude de Traitement des Hépatites Chroniques NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686-690.
21. Camps J, García-Granero M, Riezu-Boj JI et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21: 4-11.
22. Bardelli F, Mcssori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-α on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A non-B hepatitis. A meta-analysis. Clin Drug Invest 1995; 9: 239-254.
23. 3 Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC, the Australian Hepatitis C Study Group. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995; 23: 487-496.
24. Kasahara A, Hayashi N, Hiramatsu N et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291-297.
25. 5 Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
26. Hino K, Sainokami S, Shimoda K et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299-305.
27. Martintot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
28. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
29. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
30. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C, the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161-168.
31. Yamada G, Takatani M, Kishi F et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-1354.
32. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hep 1996; 3: 85-96.
33. Koizumi K, Enomoto N, Kurosaki M et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 30-35.
34. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
35. Davis GL, Lau JYN, Urdea MS et al. Quantitative detection of hepatitis C virus RNA with a solid phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 1337-1341.
36. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159: 237-241.